Anti-Peripheral Node Addressin (PNAd) Antibody, clone MECA-79

Description

• General description: Peripheral lymph node addressin (PNAd) is a mixture of glycoproteins that is expressed on high endothelial venules (HEV) and is required for lymphocyte homing. It is shown to be a ligand for CD62L (L-selectin) that is expressed on the surface of naïve and central memory T cells. PNAd is a sulfated and fucosylated glycoprotein recognized by the prototypic monoclonal antibody, MECA-79. Naïve T cells use PNAd to traffic into lymphoid organs in non-mucosal tissue sites. The interaction of PNAd with CD62L receptor is involved in tethering and rolling of lymphocytes along HEV in lymphoid tissues. Regulated appearance of PNAd+ HEVs is found during ontogeny of lymphoid tissues as well as in chronic inflammatory conditions. PNAd+ HEVs are reported to appear 24-48 h after birth in mouse peripheral lymph nodes and persist throughout life to support recirculation of lymphocytes. In humans PNAd+ HEVs are detected in fetal peripheral lymph nodes. PNAd+ HEVs are also shown to be present in several chronic inflammatory conditions, including thyroiditis, ulcerative colitis, psoriasis, rheumatoid synovitis, and cutaneous lymphomas. In murine models of inflammation, PNAd+ HEV-like vessels develop and these vessels are found to support lymphocyte recruitment. Studies on cancer in murine models and in humans have identified PNAd as a biomarker of improved disease prognosis and blockade of PNAd or its ligand, L-selectin, is shown to abrogate protective antitumor immunity in murine models. (Ref.: Sinha, RK et al. (2006). Vet. Immunol. Immunopathol. 110 (1-2): 97-108).
• Specificity: Clone MECA-79 detects Peripheral Node Addressin (PNAd) in human and mouse.
• Immunogen: Collagenase-dispersed lymph node stromal cells from BALB/c mice.
• Application: Immunohistochemistry Analysis: A 1:50 dilution from a representative lot detected Peripheral Node Addressin (PNAd) in human liver and human pancreas tissues.Western Blotting Analysis: A representative lot detected Peripheral Node Addressin (PNAd) in Western Blotting applications (Hemmerich, S., et. al. (1994). J Exp Med. 180(6):2219-26).Inhibition Analysis: A representative lot detected Peripheral Node Addressin (PNAd) in Inhibition applications (Streeter, P.R., et. al. (1988). J Cell Biol. 107(5):1853-62;Michie, S.A., et. al. (1993). Am. J. Pathol. 143(6):1688-98; Berg, E.L., et. al. (1991). J Cell Biol. 114(2):343-9).Immunoprecipitation Analysis: A representative lot detected Peripheral Node Addressin (PNAd) in Immunoprecipitation applications (Berg, E.L., et. al. (1991). J Cell Biol. 114(2):343-9).Immunohistochemistry Analysis: A representative lot detected Peripheral Node Addressin (PNAd) in Immunohistochemistry applications (Sinha, R.K., et. al. (2006). Immunology. 119(4):461-9; Streeter, P.R., et. al. (1988). J Cell Biol. 107(5):1853-62; Michie, S.A., et. al. (1993). Am J Pathol. 143(6):1688-98).Flow Cytometry Analysis: A representative lot detected Peripheral Node Addressin (PNAd) in Flow Cytometry applications (Sinha, R.K., et. al. (2006). Immunology. 119(4):461-9).
• Quality: Evaluated by Immunohistochemistry in human tonsil tissue.Immunohistochemistry Analysis: A 1:50 dilution of this antibody detected Peripheral Node Addressin (PNAd) in human tonsil tissue.
• Target description: 50-250 kDa calculated.
• Physical form: Format: Purified
• Storage and Stability: Stable for 1 year at 2-8°C from date of receipt.
• Other Notes: Concentration: Please refer to lot specific datasheet.
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.